You are here

  • Home
  • Archive
  • Volume 9, Issue 1
  • Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study

Article metrics

Article menu
XML
Epidemiology/Health services research
Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study

 

Online download statistics by month:

Online download statistics by month: January 2021 to March 2024

AbstractFullPdf
Jan 2021351336105
Feb 2021298287143
Mar 202112011956
Apr 2021716728
May 2021717020
Jun 2021817330
Jul 2021828133
Aug 2021798025
Sep 202111010942
Oct 202114213963
Nov 202112312052
Dec 2021848323
Jan 2022767614
Feb 2022475830
Mar 2022757326
Apr 202215515725
May 202212612936
Jun 202210210244
Jul 2022747415
Aug 2022798124
Sep 202211511435
Oct 202211311325
Nov 202212913350
Dec 2022818115
Jan 2023838617
Feb 202314514726
Mar 202311712025
Apr 2023848928
May 202343459
Jul 2023676826
Aug 2023788143
Sep 2023495120
Oct 2023768018
Nov 2023868618
Dec 2023585916
Jan 2024353412
Feb 2024464411
Mar 2024747541
Total382538201269